Skip to main content

Posts

Showing posts with the label pharma sector

Featured Post

Market Daily Report: Bursa Malaysia Closes Higher On BNM’s OPR Decision, Wall Street Gains

KUALA LUMPUR, Nov 5 (Bernama) -- Bursa Malaysia closed higher, buoyed by Bank Negara Malaysia’s (BNM) decision to maintain the Overnight Policy Rate (OPR) at 2.75 per cent, alongside positive cues from Wall Street. At 5 pm, the FTSE Bursa Malaysia KLCI (FBM KLCI) rose 19.30 points, or 1.19 per cent, to 1,635.86 from Wednesday’s close of 1,616.56. The benchmark index opened 6.72 points higher at 1,623.28, and fluctuated between an intraday high of 1,642.44 and a low of 1,622.62 during the trading session. However, market breadth was negative, with losers outnumbering gainers 723 to 497, while 466 counters were unchanged, 1,075 untraded and 10 suspended. Turnover rose to 3.74 billion units valued at RM3.61 billion compared with yesterday’s 2.81 billion units valued at RM2.57 billion.

Shenzhen Mindray Bio-Medical: Strong ROE Driving Earnings Growth

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE:300760) has seen its stock rise  6.8% in the past three months , prompting questions on whether strong financials are behind the move. A closer look at its return on equity (ROE) suggests the market may indeed be rewarding solid fundamentals. ROE Highlights ROE:  26% (CN¥11b net profit ÷ CN¥44b shareholders' equity) This means the company generates  CN¥0.26 in profit for every CN¥1  of equity. Its ROE is far above the  industry average of 7.6% , underscoring efficient use of capital. Earnings Performance Net income grew  16% over five years , while the broader industry saw a  3.5% decline . Strong ROE combined with above-average profit retention has supported steady earnings expansion. Dividend Policy & Retained Earnings Median payout ratio:  58%, leaving 42% for reinvestment. Despite paying out most of its profits as dividends, the company has maintained earnings growth. Shenzhen Mindra...

Why Is Recursion Pharma (RXRX) Soaring? AI-Designed Cancer Drug Sparks Hope & Investor Excitement

Stock up 9.6% — here's why investors are buzzing Breakthrough Spotlight: $Recursion Pharmaceuticals (RXRX.US)$ surged Monday after a  WIRED article  spotlighted  REC-3565 , an AI-designed MALT1 inhibitor drug showing  promising early signs in fighting blood cancer . Developed using Recursion’s cutting-edge AI platform, this molecule is something “ humans couldn’t have designed ” through traditional means, according to Peter Ray, Senior Director of Medicinal Chemistry. What Makes This Different? Only 136 molecules  were tested to develop REC-617, thanks to AI—vs. thousands in conventional drug discovery REC-3565  is now in  Phase 1 trials  for relapsed leukemia and B-cell lymphoma Ray believes this is just the start: “Each drug we develop makes the next 10 even better.” Why Investors Care: AI speeds up R&D and slashes costs Real-life patient in REC-617 trial showed  miraculous recovery signs Market sees Recursion leading the next-gen ...